In vitro model for hepatotoxicity studies based on primary human hepatocyte cultivation in a perfused 3D bioreactor system

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Knöspel, Fanny ^a   Jacobs, Frank ^b   Freyer, Nora ^a   Damm, Georg ^a   Bondt, An De ^b   Wyngaert, Ilse Van Den ^b   Snoeys, Jan ^b   Monshouwer, Mario ^b   Richter, Marco ^a   Strahl, Nadja ^a   Seehofer, Daniel ^a   Zeilinger, Katrin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Diclofenac; In vitro hepatotoxicity model; Primary human hepatocytes; Three dimensional (3D) bioreactor

Indexed keywords

AMMONIA; CYTOKERATIN 18; DICLOFENAC; DRUG METABOLITE; DRUG METABOLIZING ENZYME; VIMENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTOME;

ARTICLE; BIOREACTOR; BIOREACTOR DESIGN; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MODEL; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER CELL CULTURE; LIVER METABOLISM; LIVER TOXICITY; METABOLIC ACTIVITY ASSAY; MICROARRAY ANALYSIS; PHENOTYPE; TRANSCRIPTOMICS; CELL CULTURE; CELL CULTURE TECHNIQUE; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; METABOLISM; PATHOLOGY; TOXICITY TESTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOREACTORS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DICLOFENAC; EQUIPMENT DESIGN; HEPATOCYTES; HUMANS; TOXICITY TESTS; TRANSCRIPTOME;

EID: 84964389673     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040584     Document Type: Article

References (60)

1. Hay, M.; Thomas, D.W.; Craighead, J.L.; Economides, C.; Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32, 40-51. [CrossRef] [PubMed]
2. Li, A.P. Accurate prediction of human drug toxicity: A major challenge in drug development. Chem. Biol. Interact. 2004, 150, 3-7. [CrossRef] [PubMed]
3. Iwahori, T.; Matsuura, T.; Maehashi, H.; Sugo, K.; Saito, M.; Hosokawa, M.; Chiba, K.; Masaki, T.; Aizaki, H.; Ohkawa, K et al. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 2003, 37, 665-673. [CrossRef] [PubMed]
4. Aninat, C.; Piton, A.; Glaise, D.; Le Charpentier, T.; Langouët, S.; Morel, F.; Guguen-Guillouzo, C.; Guillouzo, A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34, 75-83. [CrossRef] [PubMed]
5. Baxter, M.; Withey, S.; Harrison, S.; Segeritz, C.P.; Zhang, F.; Atkinson-Dell, R.; Rowe, C.; Gerrard, D.T.; Sison-Young, R.; Jenkins, R et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J. Hepatol. 2015, 62, 581-589. [CrossRef] [PubMed]
6. Li, A.P. Evaluation of adverse drug properties with cryopreserved human hepatocytes and the integrated discrete multiple organ co-culture (IdMOC(TM)) system. Toxicol. Res. 2015, 31, 137-149. [CrossRef] [PubMed]
7. Gómez-Lechón, M.J.; Jover, R.; Donato, T.; Ponsoda, X.; Rodriguez, C.; Stenzel, K.G.; Klocke, R.; Paul, D.; Guillén, I.; Bort, R et al. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell. Physiol. 1998, 177, 553-562. [CrossRef]
8. Rodríguez-Antona, C.; Donato, M.T.; Boobis, A.; Edwards, R.J.; Watts, P.S.; Castell, J.V.; Gómez-Lechón, M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002, 32, 505-520. [CrossRef] [PubMed]
9. Schyschka, L.; Sánchez, J.J.; Wang, Z.; Burkhardt, B.; Müller-Vieira, U.; Zeilinger, K.; Bachmann, A.; Nadalin, S.; Damm, G.; Nussler, A.K. Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch. Toxicol. 2013, 87, 1581-1593. [CrossRef] [PubMed]
10. Ohkura, T.; Ohta, K.; Nagao, T.; Kusumoto, K.; Koeda, A.; Ueda, T.; Jomura, T.; Ikeya, T.; Ozeki, E.; Wada, K et al. Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. Drug Metab. Pharmacokinet. 2014, 29, 373-378. [CrossRef] [PubMed]
11. Khetani, S.R.; Bhatia, S.N. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 2008, 26, 120-126. [CrossRef] [PubMed]
12. Gerlach, J.C.; Encke, J.; Hole, O.; Müller, C.; Ryan, C.J.; Neuhaus, P. Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 1994, 58, 984-988. [CrossRef]
13. Zeilinger, K.; Schreiter, T.; Darnell, M.; Söderdahl, T.; Lübberstedt, M.; Dillner, B.; Knobeloch, D.; Nüssler, A.K.; Gerlach, J.C.; Andersson, T.B. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng. C Methods 2011, 17, 549-556.[CrossRef] [PubMed]
14. Hoffmann, S.A.; Müller-Vieira, U.; Biemel, K.; Knobeloch, D.; Heydel, S.; Lübberstedt, M.; Nüssler, A.K.; Andersson, T.B.; Gerlach, J.C.; Zeilinger, K. Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies. Biotechnol. Bioeng. 2012, 109, 3172-3181. [CrossRef] [PubMed]
15. Lübberstedt, M.; Müller-Vieira, U.; Biemel, K.M.; Darnell, M.; Hoffmann, S.A.; Knöspel, F.; Wönne, E.C.; Knobeloch, D.; Nüssler, A.K.; Gerlach, J.C et al. Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies. J. Tissue Eng. Regen. Med. 2015, 9, 1017-1026.[CrossRef] [PubMed]
16. Kumar, S.; Samuel, K.; Subramanian, R.; Braun, M.P.; Stearns, R.A.; Chiu, S.H.; Evans, D.C.; Baillie, T.A. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: Role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther. 2002, 303, 969-978.[CrossRef] [PubMed]
17. Boelsterli, U.A. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2003, 192, 307-322. [CrossRef]
18. Chalasani, N.; Björnsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138, 2246-2259. [CrossRef] [PubMed]
19. Banks, A.T.; Zimmerman, H.J.; Ishak, K.G.; Harter, J.G. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995, 22, 820-827.[CrossRef] [PubMed]
20. Aithal, G.P. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Expert Opin. Drug Saf. 2004, 3, 519-523. [CrossRef] [PubMed]
21. Syed, M.; Skonberg, C.; Hansen, S.H. Mitochondrial toxicity of diclofenac and its metabolites via inhibitionof oxidative phosphorylation (ATP synthesis) in rat liver mitochondria: Possible role in drug induced liver injury (DILI). Toxicol. Vitro 2016, 31, 93-102. [CrossRef] [PubMed]
22. Masubuchi, N.; Makino, C.; Murayama, N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 2007, 20, 455-464.[CrossRef] [PubMed]
23. Bort, R.; Ponsoda, X.; Jover, R.; Gómez-Lechón, M.J.; Castell, J.V. Diclofenac toxicity to hepatocytes: A role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 1999, 288, 65-72. [PubMed]
24. Mueller, D.; Müller-Vieira, U.; Biemel, K.M.; Tascher, G.; Nüssler, A.K.; Noor, F. Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure. Eur. J. Pharm. Sci. 2012, 45, 716-724. [CrossRef] [PubMed]
25. Lauer, B.; Tuschl, G.; Kling, M.; Mueller, S.O. Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem. Biol. Interact. 2009, 179, 17-24. [CrossRef] [PubMed]
26. Messner, S.; Agarkova, I.; Moritz, W.; Kelm, J.M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 2013, 87, 209-213. [CrossRef] [PubMed]
27. Gómez-Lechón, M.J.; Ponsoda, X.; O’Connor, E.; Donato, T.; Castell, J.V.; Jover, R. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem. Pharmacol. 2003, 66, 2155-2167. [CrossRef] [PubMed]
28. Prill, S.; Jaeger, M.S.; Duschl, C. Long-term microfluidic glucose and lactate monitoring in hepatic cell culture. Biomicrofluidics 2014, 8. [CrossRef] [PubMed]
29. Mueller, D.; Tascher, G.; Damm, G.; Nüssler, A.K.; Heinzle, E.; Noor, F. Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay. Cytotechnology 2013, 65, 297-305. [CrossRef] [PubMed]
30. Riss, T.L.; Moravec, R.A.; Niles, A.L.; Benink, H.A.; Worzella, T.J.; Minor, L. Cell viability assays; 1 May 2013 [Updated 29 June 2015]. In Assay Guidance Manual; Sittampalam, G.S., Coussens, N.P., Nelson, H., Arkin, M., Auld, D., Austin, C., Bejcek, B., Glicksman, M., Inglese, J., Iversen, P.W., et al., Eds.; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, USA, 2004.
31. Pace, R.T.; Burg, K.J.L. Toxic effects of resazurin on cell cultures. Cytotechnology 2015, 67, 13-17. [CrossRef] [PubMed]
32. Cassidy, W.M.; Reynolds, T.B. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J. Clin. Gastroenterol. 1994, 19, 118-121. [CrossRef] [PubMed]
33. Laine, L.; Goldkind, L.; Curtis, S.P.; Connors, L.G.; Yanqiong, Z.; Cannon, C.P. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am. J. Gastroenterol. 2009, 104, 356-362. [CrossRef] [PubMed]
34. Wang, A.G.; Xia, T.; Yuan, J.; Yu, R.A.; Yang, K.D.; Chen, X.M.; Qu, W.; Waalkes, M.P. Effects of phenobarbital on metabolism and toxicity of diclofenac sodium in rat hepatocytes in vitro. Food Chem. Toxicol. 2004, 42, 1647-1653. [CrossRef] [PubMed]
35. Borlak, J.; Chougule, A.; Singh, P.K. How useful are clinical liver function tests in in vitro human hepatotoxicity assays? Toxicol. Vitro 2014, 28, 784-795. [CrossRef] [PubMed]
36. Hinz, B.; Chevts, J.; Renner, B.; Wuttke, H.; Rau, T.; Schmidt, A.; Szelenyi, I.; Brune, K.; Werner, U. Bioavailability of diclofenac potassium at low doses. Br. J. Clin. Pharmacol 2005, 59, 80-84. [CrossRef] [PubMed]
37. Hackstein, H.; Mohl, W.; Püschel, W.; Stallmach, A.; Zeitz, M. Diclofenac-associated acute cholestatis hepatitis. Z. Gastroenterol. 1998, 36, 385-389. [PubMed]
38. Breen, E.G.; McNicholl, J.; Cosgrove, E.; McCabe, J.; Stevens, F.M. Fatal hepatitis associated with diclofenac. Gut 1986, 27, 1390-1393. [CrossRef] [PubMed]
39. Helfgott, S.M.; Sandberg-Cook, J.; Zakim, D.; Nestler, J. Diclofenac-associated hepatotoxicity. JAMA 1990, 264, 2660-2662. [CrossRef] [PubMed]
40. Sallustio, B.C.; Holbrook, F.L. In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac. Drug Metab. Dispos. 2001, 29, 1535-1538. [PubMed]
41. Kretz-Rommel, A.; Boelsterli, U.A. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 1995, 22, 213-222. [CrossRef] [PubMed]
42. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 2004, 25, 193-200. [CrossRef] [PubMed]
43. Guguen-Guillouzo, C.; Guillouzo, A. General review on in vitro hepatocyte models and their applications. Methods Mol. Biol. 2010, 640, 1-40. [PubMed]
44. Rodrigues, R.M.; Heymans, A.; de Boe, V.; Sachinidis, A.; Chaudhari, U.; Govaere, O.; Roskams, T.; Vanhaecke, T.; Rogiers, V.; de Kock, J. Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems. Toxicol. Lett. 2016, 240, 50-59. [CrossRef] [PubMed]
45. Lagas, J.S.; van der Kruijssen, C.M.; van de Wetering, K.; Beijnen, J.H.; Schinkel, A.H. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab. Dispos. 2009, 37, 129-136.[CrossRef] [PubMed]
46. Liu, Z.X.; Govindarajan, S.; Kaplowitz, N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004, 127, 1760-1774. [CrossRef] [PubMed]
47. Campion, S.N.; Johnson, R.; Aleksunes, L.M.; Goedken, M.J.; van Rooijen, N.; Scheffer, G.L.; Cherrington, N.J.; Manautou, J.E. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G294-G304. [CrossRef] [PubMed]
48. Herpers, B.; Wink, S.; Fredriksson, L.; Di, Z.; Hendriks, G.; Vrieling, H.; de Bont, H.; van de Water, B. Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-_B activation and sensitizes toward TNF-induced cytotoxicity. Arch. Toxicol. 2015. [CrossRef] [PubMed]
49. Zhang, J.D.; Berntenis, N.; Roth, A.; Ebeling, M. Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicity. Pharmacogenom. J. 2014, 14, 208-216.[CrossRef] [PubMed]
50. Fredriksson, L.; Herpers, B.; Benedetti, G.; Matadin, Q.; Puigvert, J.C.; de Bont, H.; Dragovic, S.;Vermeulen, N.P.; Commandeur, J.N.; Danen, E et al. Diclofenac inhibits tumornecrosisfactor- -induced nuclearfactor-_B activation causing synergistic hepatocyte apoptosis. Hepatology 2011, 53, 2027-2041. [CrossRef] [PubMed]
51. Damm, G.; Pfeiffer, E.; Burkhardt, B.; Vermehren, J.; Nüssler, A.K.; Weiss, T.S. Human parenchymal and non-parenchymal liver cell isolation, culture and characterization. Hepatol. Int. 2013, 7, 951-958. [CrossRef] [PubMed]
52. Pfeiffer, E.; Kegel, V.; Zeilinger, K.; Hengstler, J.G.; Nüssler, A.K.; Seehofer, D.; Damm, G. Featured Article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp. Biol. Med. 2015, 240, 645-656. [CrossRef] [PubMed]
53. Gentleman, R.C.; Carey, V.J.; Bates, D.M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, B.; Gautier, L.; Ge, Y.; Gentry, J et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 2004, 5, R80. [CrossRef] [PubMed]
54. Dai, M.; Wang, P.; Boyd, A.D.; Kostov, G.; Athey, B.; Jones, E.G.; Bunney, W.E.; Myers, R.M.; Speed, T.P.; Akil, H et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33, e175. [CrossRef] [PubMed]
55. Irizarry, R.A.; Hobbs, B.; Collin, F.; Beazer-Barclay, Y.D.; Antonellis, K.J.; Scherf, U.; Speed, T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4, 249-264. [CrossRef] [PubMed]
56. Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3, 1-28. [CrossRef] [PubMed]
57. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [CrossRef] [PubMed]
58. Hochberg, Y.; Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 1990, 9, 811-818. [CrossRef] [PubMed]
59. Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25, 25-29. [CrossRef] [PubMed]
60. Raghavan, N.; de Bondt, A.M.; Talloen, W.; Moechars, D.; Göhlmann, H.W.; Amaratunga, D. The high-level similarity of some disparate gene expression measures. Bioinformatics 2007, 23, 3032-3038. [CrossRef] [PubMed]